Welcome to our dedicated page for scPharmaceuticals news (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on scPharmaceuticals stock.
scPharmaceuticals Inc. (NASDAQ: SCPH) is a clinical-stage pharmaceutical company dedicated to revolutionizing the administration of infused therapies. Headquartered in Burlington, MA, the company is spearheading advancements in patient care through its proprietary platform that enables subcutaneous administration of treatments traditionally limited to intravenous (IV) delivery. This innovative approach aims not only to improve patient outcomes but also to significantly reduce healthcare costs.
The company’s flagship product, Furoscix, is a patented furosemide formulation designed for subcutaneous use via the wearable, portable sc2Wear Infusor. Furoscix targets the treatment of edema in heart failure patients, offering them a convenient and effective alternative to traditional IV therapies. With a focus on self-administration, scPharmaceuticals is paving the way for outpatient care of acute conditions.
Recent achievements have bolstered scPharmaceuticals’ position in the pharmaceutical landscape. The company generated $6.1 million in product revenue for the first quarter of 2024, a marked increase from $2.1 million in the same period of the previous year. This growth reflects the rising demand for Furoscix and the successful execution of their commercial strategy.
Moreover, scPharmaceuticals is actively pursuing long-term growth initiatives for Furoscix. These include expanding its indication to include NYHA Class IV heart failure patients and chronic kidney disease, both pending FDA review. Another promising development is the initiation of a pharmacokinetic study to support a low-volume auto-injector version of Furoscix, aimed at providing greater flexibility in treatment options.
The company’s financial health remains robust, with strategic investments in research and development, as well as selling, general, and administrative expenses to support its growth trajectory. Despite reporting a net loss of $14.1 million for the first quarter of 2024, compared to $11.2 million for the first quarter of 2023, scPharmaceuticals remains focused on driving forward with its innovative solutions and strategic partnerships.
For more information, please visit www.scPharmaceuticals.com.
scPharmaceuticals (Nasdaq: SCPH) announced FDA approval for FUROSCIX®, a proprietary furosemide formulation for treating congestion due to fluid overload in adult patients with chronic heart failure (NYHA Class II/III). FUROSCIX, the first FDA-approved subcutaneous loop diuretic, offers IV-equivalent diuresis, allowing at-home administration via the On-Body Infusor, targeting a significant U.S. market of $5.9 billion. The commercial launch is set for Q1 2023, aiming to enhance patient care and reduce hospital admissions for over 7 million heart failure patients.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced two poster presentations at the Heart Failure Society of America (HFSA) 2022 Annual Meeting, highlighting the clinical benefits of FUROSCIX® (furosemide injection) in treating heart failure congestion at home. Data from a pilot study showed that patients using FUROSCIX experienced significantly greater weight reduction and improved dyspnea scores compared to those on oral diuretics. The company anticipates a robust launch for FUROSCIX following its October 8 PDUFA date, pending FDA approval.
scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company specializing in optimizing infused therapies, announced that CEO John Tucker will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York. His presentation will be available for on-demand viewing starting September 12 at 7:00 am ET. Attendees can also schedule virtual one-on-one meetings with Tucker during the conference. The replay will be accessible in the Investor Relations section of scPharmaceuticals' website.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced FDA acceptance of their FUROSCIX NDA, scheduled for review on October 8, 2022. The company is preparing for a Q4 2022 launch, pending approval. Financially, scPharmaceuticals ended Q2 2022 with $56 million in cash, down from $75.5 million at year-end 2021. They reported a net loss of $9.7 million for Q2 2022, up from $7.1 million in Q2 2021. Research and development expenses rose to $5.1 million, and general and administrative expenses increased to $4.3 million. The company projects a net loss between $43 million and $48 million for 2022.
scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will participate in a panel discussion on heart failure therapeutics on July 14, 2022, at 10:00 a.m. ET. The event is hosted by Maxim Group LLC and will be available live on M-Vest. The company is dedicated to developing products that enhance infused therapy delivery, improve patient care, and lower healthcare costs. Their focus includes self-administered IV-strength treatments for heart failure and infectious diseases.
scPharmaceuticals Inc. (SCPH) announced positive results from its AT HOME-HF Pilot study, evaluating FUROSCIX for chronic heart failure patients. The study showed a 37% reduction in heart failure hospitalizations and improvements in symptoms and quality of life. Subjects using FUROSCIX experienced greater weight loss and higher Kansas City Cardiomyopathy Questionnaire scores. Although there were some mild adverse events, the tolerability profile was deemed acceptable. With a PDUFA date set for October 8, 2022, the company aims for a Q4 2022 commercial launch of FUROSCIX, pending regulatory approval.
scPharmaceuticals Inc. (SCPH) is hosting a virtual investor event on July 13, 2022, at 10:00 AM EDT to discuss FUROSCIX (furosemide) 80mg/10mL, an investigational treatment for heart failure patients. Key Opinion Leaders Dr. Daniel Bensimhon and James Kenney will present insights on the treatment landscape and the economic implications of heart failure management. The event will also feature discussions from scPharmaceuticals' leadership about the potential benefits of FUROSCIX in reducing healthcare costs and improving patient care.
scPharmaceuticals (Nasdaq: SCPH) announced two abstracts from the FREEDOM-HF study will be presented at the AAHFN Annual Meeting in Orlando on June 15-18. The study's primary results indicate that patients treated with FUROSCIX incurred nearly $18,000 less in 30-day heart failure-related costs compared to traditional inpatient care. The New Drug Application for FUROSCIX is under review, with a Prescription Drug User Fee Act date set for October 8, 2022. The company is gearing up for a potential Q4 2022 commercial launch if approved.
scPharmaceuticals Inc. (Nasdaq: SCPH) has announced that CEO John Tucker will present at the Jefferies Healthcare Conference on June 9, 2022, at 2:00 PM EDT in New York City. The presentation will focus on the company's mission to develop and commercialize products aimed at optimizing therapies and reducing healthcare costs. A live webcast will be available on their website under the Investor Relations section. Headquartered in Burlington, MA, scPharmaceuticals specializes in outpatient treatments for acute conditions, particularly in heart failure and infectious diseases.
scPharmaceuticals Inc. (Nasdaq: SCPH), a company dedicated to innovative healthcare solutions, announced its CEO John Tucker will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 3:00 PM EDT in Miami, FL. The conference aims to highlight advancements in outpatient care and healthcare cost reduction. A live webcast of the presentation will be available on the company's Investor Relations webpage. scPharmaceuticals specializes in developing products for outpatient care, focusing on IV-strength treatments for heart failure and infectious diseases.
FAQ
What is the current stock price of scPharmaceuticals (SCPH)?
What is the market cap of scPharmaceuticals (SCPH)?
What is scPharmaceuticals Inc.?
What is Furoscix?
Where is scPharmaceuticals headquartered?
How much revenue did scPharmaceuticals generate in Q1 2024?
What are the future plans for Furoscix?
What are the benefits of scPharmaceuticals' platform?
What recent financial results did scPharmaceuticals report?
What is the sc2Wear Infusor?
Who are the key contacts for more information?
What is scPharmaceuticals' approach to outpatient care?
